CL2017003096A1 - Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis - Google Patents

Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis

Info

Publication number
CL2017003096A1
CL2017003096A1 CL2017003096A CL2017003096A CL2017003096A1 CL 2017003096 A1 CL2017003096 A1 CL 2017003096A1 CL 2017003096 A CL2017003096 A CL 2017003096A CL 2017003096 A CL2017003096 A CL 2017003096A CL 2017003096 A1 CL2017003096 A1 CL 2017003096A1
Authority
CL
Chile
Prior art keywords
treatment
mucopolysaccharidosis
adeno
viral vectors
associated viral
Prior art date
Application number
CL2017003096A
Other languages
English (en)
Inventor
Tubert Maria Fátima Bosch
Haurigot Virginia Areba
Mallol Sandra Motas
Original Assignee
Univ Barcelona Autonoma
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Barcelona Autonoma, Esteve Pharmaceuticals Sa filed Critical Univ Barcelona Autonoma
Publication of CL2017003096A1 publication Critical patent/CL2017003096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona nuevos vectores derivados de virus adeno-asociados y composiciones farmacéuticas que los contienen para el tratamiento de trastornos de almacenamiento lisosómico y especialmente, para el tratamiento de mucopolisacaridosis Tipo II.
CL2017003096A 2015-06-05 2017-12-04 Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis CL2017003096A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382297.8A EP3101125A1 (en) 2015-06-05 2015-06-05 Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Publications (1)

Publication Number Publication Date
CL2017003096A1 true CL2017003096A1 (es) 2018-08-10

Family

ID=53398018

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003096A CL2017003096A1 (es) 2015-06-05 2017-12-04 Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis

Country Status (21)

Country Link
US (1) US10617771B2 (es)
EP (2) EP3101125A1 (es)
JP (1) JP6850736B2 (es)
KR (1) KR102609858B1 (es)
CN (1) CN108138154B (es)
AU (1) AU2016273343B2 (es)
BR (1) BR112017025892A2 (es)
CA (1) CA2988201C (es)
CL (1) CL2017003096A1 (es)
CO (1) CO2017012562A2 (es)
ES (1) ES2790834T3 (es)
IL (1) IL255939B (es)
MX (1) MX2017015725A (es)
MY (1) MY184586A (es)
PH (1) PH12017502192A1 (es)
PT (1) PT3303576T (es)
RU (1) RU2744593C2 (es)
TN (1) TN2017000506A1 (es)
UA (1) UA125373C2 (es)
WO (1) WO2016193431A1 (es)
ZA (1) ZA201708039B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
EP3194430A1 (en) 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3227449B1 (en) 2014-12-05 2020-07-15 Universitat Autònoma de Barcelona Viral vectors for the treatment of diabetes
ES2900973T3 (es) 2015-01-07 2022-03-21 UNIV AUTòNOMA DE BARCELONA Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
KR20190008237A (ko) * 2016-04-15 2019-01-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
BR112019021569A2 (pt) * 2017-04-14 2020-05-12 Regenxbio Inc. Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
JP7449223B2 (ja) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を治療するための遺伝子療法
CN108795985A (zh) * 2018-05-31 2018-11-13 深圳市免疫基因治疗研究院 一种黏多糖贮积症慢病毒载体、慢病毒及其制备方法和应用
CN108715867A (zh) * 2018-05-31 2018-10-30 深圳市免疫基因治疗研究院 一种Sanfilippo B综合症慢病毒载体、慢病毒及其制备方法和应用
EP3829619A4 (en) * 2018-07-27 2022-05-18 REGENXBIO Inc. TREATMENT OF MUCOPOLYSACCHARIDOSE IVA
CN113423828A (zh) * 2018-11-15 2021-09-21 埃斯蒂维制药有限公司 粘多糖累积病iva型的动物模型
TW202039856A (zh) * 2019-03-28 2020-11-01 西班牙商艾斯提夫製藥股份有限公司 製造重組病毒載體之方法
MX2022007135A (es) * 2019-12-10 2022-09-19 Takeda Pharmaceuticals Co Vectores de virus adenoasociados para el tratamiento del síndrome de hunter.
AU2021252515A1 (en) * 2020-04-06 2022-10-27 Homology Medicines, Inc. Adeno-associated virus compositions for IDS gene transfer and methods of use thereof
CN111718947B (zh) * 2020-06-18 2022-08-23 舒泰神（北京）生物制药股份有限公司 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途
CN114480454B (zh) * 2020-10-27 2024-03-29 华东理工大学 用于治疗粘多糖贮积症ⅱ型的腺相关病毒载体、药物及其应用
CA3209611A1 (en) 2021-02-10 2022-08-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
WO2022221421A2 (en) * 2021-04-13 2022-10-20 Capsida, Inc. Aav compositions with high brain expression for treating mucopolysaccharidosis ii
KR20240045299A (ko) * 2021-08-18 2024-04-05 조인트-스톡 컴퍼니 "제네리움" 치료 효소의 표적화 전달

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100762945B1 (ko) * 2004-09-08 2007-10-04 진동규 동물 세포주를 이용한 이듀로네이트-설파타제의 발현 방법및 그 발현을 위한 세포주
CN102027110A (zh) * 2008-01-18 2011-04-20 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
EP3533467B1 (en) * 2009-10-09 2023-07-26 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
WO2012063984A1 (ko) * 2010-11-12 2012-05-18 주식회사 녹십자 개량형 이듀로네이트-2-설파타제 및 이의 용도
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
JP2014511694A (ja) * 2011-04-03 2014-05-19 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
WO2013151666A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
DK3107562T3 (da) * 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner

Also Published As

Publication number Publication date
CN108138154B (zh) 2022-01-18
IL255939A (en) 2018-01-31
KR102609858B1 (ko) 2023-12-05
RU2017142006A3 (es) 2020-02-03
AU2016273343B2 (en) 2022-04-28
JP2018517414A (ja) 2018-07-05
US10617771B2 (en) 2020-04-14
RU2744593C2 (ru) 2021-03-11
ZA201708039B (en) 2018-11-28
CA2988201A1 (en) 2016-12-08
CO2017012562A2 (es) 2018-02-28
CA2988201C (en) 2024-01-16
PT3303576T (pt) 2020-05-08
BR112017025892A2 (pt) 2018-08-14
WO2016193431A1 (en) 2016-12-08
MX2017015725A (es) 2018-08-15
EP3303576B1 (en) 2020-02-12
MY184586A (en) 2021-04-06
TN2017000506A1 (en) 2019-04-12
RU2017142006A (ru) 2019-07-09
JP6850736B2 (ja) 2021-03-31
UA125373C2 (uk) 2022-03-02
KR20180012843A (ko) 2018-02-06
AU2016273343A1 (en) 2017-12-21
PH12017502192A1 (en) 2018-06-11
IL255939B (en) 2021-05-31
US20180169272A1 (en) 2018-06-21
CN108138154A (zh) 2018-06-08
ES2790834T3 (es) 2020-10-29
EP3303576A1 (en) 2018-04-11
EP3101125A1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
AR109752A1 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CY1123853T1 (el) Ρυθμιστες nrf2
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2016003212A1 (es) Derivados de indolín-2-ona o pirrolo-piridín-2-ona.
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2016002333A1 (es) Terapia genica para la retinitis pigmentaria.
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2016001745A1 (es) Ácido (s)-3'-metil-abscísico y ésteres del mismo
CO2020015942A2 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida